Different brands of intravenous immunoglobulin for primary immunodeficiencies: How to choose the best option for the patient?

Expert Review of Clinical Immunology

Volumn 11, Issue 11, 2015, Pages 1229-1243

  Abolhassani, Hasssan ^a,b   Asgardoon, Mohammad Hossein ^a   Rezaei, Nima ^a,c   Hammarstrom, Lennart ^b   Aghamohammadi, Asghar ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

formulations; intravenous immunoglobulin; primary immunodeficiency disease; risk factors

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A; SODIUM; SUGAR;

ATAXIA TELANGIECTASIA; BIOLOGICAL ACTIVITY; COMBINED IMMUNODEFICIENCY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INTERACTION; DRUG MONITORING; FRACTIONATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFUSION RATE; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; NETHERTON DISEASE; OSMOLALITY; OSMOLARITY; PATIENT MONITORING; PH; PLASMA; PROTEIN PURIFICATION; REVIEW; SIDE EFFECT; SUBSTITUTION THERAPY; VIRUS INACTIVATION; CHEMISTRY; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; QUALITY OF LIFE;

HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; QUALITY OF LIFE;

EID: 84945450659     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1079485     Document Type: Review

References (96)

1. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014;5:162
2. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010;125(2 Suppl 2):S182-94
3. Aghamohammadi A, Mohammadinejad P, Abolhassani H, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol 2014; 34(4):478-90
4. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008;28(2):413-37; x
5. Wood P, Stanworth S, Burton J, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007;149(3):410-23
6. Rezaei N, Abolhassani H, Aghamohammadi A, Ochs HD. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol 2011;7(3):301-16
7. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American academy of allergy, Asthma and immunology. J Allergy Clin Immunol 2006;117(4 Suppl):S525-53
8. Gathmann B, Binder N, Ehl S, Kindle G; Party ERW. The European internet-based patient and research database for primary immunodeficiencies: update 2011. Clin Exp Immunol 2012;167(3):479-91
9. Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 2012;32(6): 1180-92
10. Hernandez-Trujillo HS, Chapel H, Lo Re V III, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol 2012;169(1):57-69
11. Stiehm ER, Orange JS, Ballow M, Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr 2010;57(1): 185-218
12. Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clinical immunology 2010; 135(2):255-63
13. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gamma-globulin. Vox Sang 1962;7:157-74
14. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008;28(4):737-64; viii
15. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008; 28(4):765-78; viii
16. Silvergleid A, Berger M, Sehrier SL, et al. Overview of intravenous immune globulin (IVIG) therapy. In: Post TW, editor, UpToDate, Waltham, MA. [Last accessed 25 February 2015]
17. Poelsler G, Berting A, Kindermann J, et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sang 2008;94(3):184-92
18. Terpstra FG, Parkkinen J, Tolo H, et al. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang 2006;90(1):21-32
19. Kreil TR, Wieser A, Berting A, et al. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives. Transfusion 2006;46(7):1143-51
20. Burnouf T, Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006; 13(5):320-8
21. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010;98(1):12-28
22. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005;62(16 Suppl 3):S5-11
23. Papista C, Berthelot L, Monteiro RC. Dysfunctions of the Iga system: a common link between intestinal and renal diseases. Cell Mol Immunol 2011;8(2):126-34
24. Cooper MD, Lanier LL, Conley ME, Puck JM. Immunodeficiency disorders. hematology/the education program of the american society of hematology. Hematology Am Soc Hematol Educ Program 2003;314-30
25. Kaveri SV, Maddur MS, Hegde P, et al. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 2011;164(Suppl 2):2-5
26. Elluru SR, Kaveri SV, Bayry J. The protective role of immunoglobulins in fungal infections and inflammation. Semin Immunopathol 2015;37(2):187-97
27. Siedlar M, Strach M, Bukowska-Strakova K, et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16+ + monocytes in common variable immunodeficiency (CVID) patients. Clin immunol 2011;139(2):122-32
28. Paquin-Proulx D, Santos BA, Carvalho KI, et al. IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID. PLoS One 2013;8(10): e75199
29. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006;6(4):592-9
30. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007; 87(3):206-18
31. Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy 2005;25(11 Pt 2):78S-84S
32. Gurcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev 2010;9(8):553-9
33. Buehler AM, Flato UP, Ferri CP, Fernandes JG. Is there evidence for recommending specific intravenous immunoglobulin formulations? A systematic review of head-to-head randomized controlled trials. Eur J Pharmacol 2015;747: 96-104
34. Saeedian M, Randhawa I. Immunoglobulin replacement therapy: a twenty-year review and current update. Int Arch Allergy Immunol 2014;164(2):151-66
35. Gelfand EW. Differences between IGIV products: Impact on clinical outcome. Int Immunopharmacol 2006;6(4):592-9
36. Pac M. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children]. Pol Merkur Lekarski 2011;30(180):413-16
37. Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am 2008;28(4):833-49, ix.
38. Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2004;93(2):160-5
39. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002;109(6): 1001-4
40. Pourpak Z, Aghamohammadi A, Sedighipour L, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect 2006;39(2): 114-20
41. Buckley RH. Immunoglobulin G subclass deficiency: fact or fancy? Curr Allergy Asthma Rep 2002;2(5):356-60
42. Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag 2010;6:1-10
43. Kobrynski LJ. Combined immune deficiencies in children. J Infus Nurs 2006; 29(4):206-13
44. DeWitt CA, Bishop AB, Buescher LS, Stone SP. Hyperimmunoglobulin E syndrome: two cases and a review of the literature. J Am Acad Dermatol 2006;54(5): 855-65
45. Mohammadinejad P, Abolhassani H, Aghamohammadi A, et al. Class switch recombination process in ataxia telangiectasia patients with elevated serum levels of IgM. J Immunoassay Immunochem 2015;36(1):16-26
46. Aghamohammadi A, Imai K, Moazzami K, et al. Ataxia-telangiectasia in a patient presenting with hyper-immunoglobulin M syndrome. J Investig Allergol Clin Immunol 2010;20(5):442-5
47. Renner ED, Hartl D, Rylaarsdam S, et al. Comel-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 2009;124(3):536-43
48. Weemaes CM, van Tol MJ, Wang J, et al. Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects. Eur J Hum Genet 2013;21(11): 1219-25
49. Wani MA, Haynes LD, Kim J, et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci USA 2006;103(13):5084-9
50. Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011;31(3): 315-22
51. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125(6): 1354-1360 e1354
52. Ballow M. Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current data. Ann Allergy Asthma Immunol 2013;111(6 Suppl):S2-5
53. Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev 2010;24(Suppl 1): S28-50
54. Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine 1985;64(3):145-56
55. Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993;86(1):31-42
56. Hansel TT, Haeney MR, Thompson RA. Primary hypogammaglobulinaemia and arthritis. BMJ 1987;295(6591):174-5
57. Aghamohammadi A, Allahverdi A, Abolhassani H, et al. Comparison of pulmonary diseases in common variable immunodeficiency and X-linked agammaglobulinaemia. Respirology 2010; 15(2):289-95
58. Mohammadinejad P, Aghamohammadi A, Abolhassani H, et al. Pediatric patients with common variable immunodeficiency: long-term follow-up. J Investig Allergol Clin Immunol 2012;22(3):208-14
59. Aghamohammadi A, Farhoudi A, Moin M, et al. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol 2005;12(7):825-32
60. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clinical immunology 1999; 92(1):34-48
61. Aghamohammadi A, Moin M, Farhoudi A, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004;40(2):113-18
62. Aghamohammadi A, Tavassoli M, Abolhassani H, et al. Infectious and non-infectious complications among undiagnosed patients with common variable immunodeficiency. Iran J Pediatr 2009; 19(4):367-75
63. Abolhassani H, Akbari F, Mirminachi B, et al. Morbidity and mortality of iranian patients with hyper IgM syndrome: a clinical analysis. Iran J Immunol 2014; 11(2):123-33
64. Shaghaghi MR, Aghamohammadi A, Abolhassani H, et al. Mortality and morbidity in patients with X-linked agammaglobulinemia. J Clin Immunol 2012;32:297-7
65. Aghamohammadi A, Pouladi N, Parvaneh N, et al. Mortality and morbidity in common variable immunodeficiency. J Trop Pediatrics 2007;53(1):32-8
66. Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract 2013;1(6): 558-66
67. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol 2011;11(6): 532-8
68. Malbran A, Larrauri B, Juri MC, Fernandez Romero DS. [Adverse events in 1395 infusions with different intravenous gammaglobulin products]. Medicina (B Aires) 2013;73(5):433-7
69. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006;6(4):535-42
70. Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36(2): 83-6
71. Gupta N, Ahmed I, Nissel-Horowitz S, et al. Intravenous gammaglobulin-associated acute renal failure. Am J Hematol 2001; 66(2):151-2
72. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008;51(3):491-503
73. Bern M. Clinically significant pseudohyponatremia. Am J Hematol 2006; 81(7):558-9
74. Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 2003; 73(2):97-100
75. Miller JL, Petteway SR Jr, Lee DC. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. J Allergy Clin Immunol 2001;108(4 Suppl): S91-4
76. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003; 60(11):1822-4
77. Mizrahi M, Adar T, Orenbuch-Harroch E, Elitzur Y. Non-ST elevation myocardial infraction after high dose intravenous immunoglobulin infusion. Case Rep Med 2009;2009:861370
78. Katz KA, Hivnor CM, Geist DE, et al. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003;139(8): 991-3
79. Byrne NP, Henry JC, Herrmann DN, et al. Neuropathologic findings in a Guillain-Barre patient with strokes after IVIg therapy. Neurology 2002;59(3):458-61
80. Mizrahi M. The hypercoagulability of intravenous immunoglobulin. Clin Adv Hematol Oncol 2011;9(1):49-50
81. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65(1):30-4
82. Funk MB, Gross N, Gross S, et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013; 105(1):54-64
83. Notarangelo LD, Plebani A, Mazzolari E, et al. Genetic causes of bronchiectasis: Primary immune deficiencies and the lung. Respiration 2007;74(3):264-75
84. de Gracia J, Vendrell M, Alvarez A, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004;4(6):745-53
85. Chen Y, Stirling RG, Paul E, et al. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immun 2011; 127(6):1414-17
86. Warrier I, Bussel JB, Valdez L, et al. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol 1997;19(3):197-201
87. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008;48(8):1598-601
88. Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012;129(3):628-34
89. IUIS/WHO notice. Appropriate uses of human immunoglobulin in clinical practice. Clin Exp Immunol 1983;52(2):417-22
90. WHO. WHO recommendations for the production, control, and regulation of human plasma for fractionation. World Health Organization; Geneva, Switzerland: 2005
91. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003;43(10): 1460-80
92. Guillevin L. [Indications for immunoglobulins. Recommendations of CEDIT of AP-HP in 2006]. Rev Med Interne 2007;28(Spec No 1):1-3
93. Frauger E, Grassi J, Pradel V, et al. Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals. Fundam Clin Pharmacol 2011; 25(6):753-61
94. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007;6(4): 257-9
95. Katz U, Kishner I, Magalashvili D, et al. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006;39(6):513-17
96. Gelfand EW. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 2005;28(6):366-74